Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
14.54
+0.18 (1.25%)
At close: Mar 28, 2025, 4:00 PM
14.53
-0.01 (-0.05%)
After-hours: Mar 28, 2025, 7:56 PM EDT
Cartesian Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Cartesian Therapeutics stock have an average target of 40.83, with a low estimate of 39 and a high estimate of 43. The average target predicts an increase of 180.81% from the current stock price of 14.54.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cartesian Therapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 6 | 6 | 6 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $45 → $40 | Strong Buy | Maintains | $45 → $40 | +175.10% | Mar 14, 2025 |
| Needham | Needham | Strong Buy Reiterates $41 | Strong Buy | Reiterates | $41 | +181.98% | Mar 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $45 | Strong Buy | Reiterates | $45 | +209.49% | Jan 28, 2025 |
| Needham | Needham | Strong Buy Reiterates $41 | Strong Buy | Reiterates | $41 | +181.98% | Jan 27, 2025 |
| Needham | Needham | Strong Buy Reiterates $41 | Strong Buy | Reiterates | $41 | +181.98% | Jan 13, 2025 |
Financial Forecast
Revenue This Year
5.61M
from 38.91M
Decreased by -85.58%
Revenue Next Year
8.98M
from 5.61M
Increased by 60.00%
EPS This Year
-3.11
from -4.49
EPS Next Year
-3.64
from -3.11
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 25.2M | 25.2M | 21.0M | ||
| Avg | 5.6M | 9.0M | 5.1M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -35.2% | 349.2% | 134.0% | ||
| Avg | -85.6% | 60.0% | -43.2% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -2.26 | -2.07 | -3.53 |
| Avg | -3.11 | -3.64 | -4.55 |
| Low | -3.81 | -4.36 | -5.83 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.